Eli Lilly scores upbeat PhIII data for GLP1 drug in busy diabetes market

Ryan McBride Eli Lilly ($ LLY) has added to a body of positive Phase III data for its once-weekly GLP-1 candidate dulaglutide, with two more late-stage studies that have met their ...
Page 9 of 9« First...56789
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS